Medical Developments International Ltd. engages in the manufacture and distribution of pharmaceutical drugs, medical, and veterinary equipment. The firm operates in two segments: Pain Management and Respiratory. The Pain Management segment is engaged in the supply of analgesia for acute and procedural pain. The firm manufactures an inhaled analgesic, Penthrox (the Green Whistle), at manufacturing facilities at Scoresby and Springvale in Victoria, Australia. Penthrox is sold into domestic and international markets through distribution partnerships and direct in-market capability. The Respiratory segment is a supplier of respiratory products including asthma and chronic obstructive pulmonary disease (COPD) space chambers, peak flow meters, portable nebulizers and silicone face masks. The respiratory supplies into Australia, the United States of America, Europe, and Asia through partnerships with distributors.
Medical Developments International Limitedの主要な財務諸表は何ですか?
最新の財務諸表(Form-10K)によると、Medical Developments International Limitedの総資産は$66で、純损失は$0です。
MDDVFの主要な財務比率は何ですか?
Medical Developments International Limitedの流動比率は6、純利益率は0、1株当たり売上高は$0.34です。
Medical Developments International Limitedの収益はセグメントまたは地域別にどのように分けられていますか?
Medical Developments International Limited 最大收入来源是 Pain Management,在最近的收益报告中收入为 21,296,000。就地区而言, Australia 是 Medical Developments International Limited 的主要市场,收入为 15,364,000。
Medical Developments International Limitedは収益を上げていますか?
不、最新の財務諸表によると、Medical Developments International Limitedの純损失は$0です。
Medical Developments International Limitedに負債はありますか?
是的、Medical Developments International Limitedの負債は11です。
Medical Developments International Limitedの発行済株式数は何株ですか?
Medical Developments International Limitedの総発行済株式数は112.65株です。